Proteomic profile of CSF obtained at the time of diagnosis determines amyotrophic lateral sclerosis progression and survival: CXCL7 levels in disease prognosis and survival
Brain Pathology · 2026-09 · 36 (5)
DOI: 10.1111/bpa.70089 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain Pathology, online erschienen am 03.03.2026. Verfasst von Sergio Roca-Pereira und 19 weiteren Autor:innen. Beteiligte Einrichtung: Neurology and Neurogenetics Group- Neuroscience Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spa…. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, beta-Thromboglobulin. Die Arbeit nennt 128 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Instituto de Salud Carlos III, Fundació Catalana d'Esclerosi Lateral Amiotròfica (ELA) Miquel Valls, Elles contra l'Esclerosi Lateral Amiotròfica (ELA).
Abstract (Originalsprache)
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease primarily affecting motor neurons. Neurofilament light chain (NfL) is the most established prognostic biomarker; however, its diagnostic resolution is limited, particularly within intermediate concentration ranges, and it does not capture the molecular heterogeneity of ALS. This study aimed to identify complementary cerebrospinal fluid (CSF) biomarkers and pathway‐specific signatures through a non‐targeted multiomic approach. We performed SWATH‐MS‐based proteomics and LC–MS/MS lipidomics on CSF from ALS patients stratified by survival (ALS‐SS and ALS‐LS) and healthy controls. Weighted protein co‐expression network analysis (WPCNA) was applied to identify biologically coherent protein modules associated with disease phenotype and progression. Top biomarker candidates were further evaluated using immunoassays in an independent cohort. Post‐mortem ALS spinal cord tissues were analyzed to explore the pathophysiological relevance of identified proteins. CSF proteomic profiles robustly distinguished ALS patients from controls and stratified patient subgroups by survival, revealing a molecular signature characterized by inflammation, downregulation of detoxification mechanisms, and synaptic dysregulation in aggressive disease forms. In contrast, lipidomic profiles showed limited discriminatory power. WPCNA identified modular proteomic signatures capturing ALS heterogeneity, and machine learning models based on these profiles yielded optimal biomarker panels for diagnosis and prognosis. CXCL7 emerged as a promising complementary biomarker, and shed light in disease physiopathology. Immunoassay validation supported the diagnostic and prognostic potential of CXCL7 and its association with survival time. Histopathological analysis further confirmed CXCL7 localization in anterior horn motor neurons, despite no detectable changes in whole spinal cord lysates at late disease stages. Comprehensive CSF proteomic profiling, combined with network‐based analysis, enhances our understanding of ALS molecular heterogeneity and provides a framework for precision biomarker discovery. CXCL7 complements NfL as a diagnostic and prognostic biomarker, supporting improved patient stratification and advancing the development of personalized therapeutic strategies in ALS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurology and Neurogenetics Group- Neuroscience Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
- Network Centre of Biomedical Research of Neurodegenerative Diseases (CIBERNED), Institute of Health Carlos III, L'Hospitalet de Llobregat, Barcelona, Spain.
- Functional Unit of Amyotrophic Lateral Sclerosis (UFELA), Service of Neurology, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.
- Neuromuscular Unit and ERN-NMD Group, Department of Neurology, Hospital Universitario y Politécnico La Fe and IIS La Fe, Valencia, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Department of Medicine, Universitat de València, Valencia, Spain.
- Proteomics Unit, Clinical Neuroproteomics Laboratory, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Sp…
ORCID-Profile: Sergio Roca-Pereira, Yaiza López-Sampere, Pol Mengod-Soler, Mario Peña-Fonteboa, Carla Marco, Alejandro Caravaca-Puchades, Raúl Domínguez, Juan Francisco Vázquez-Costa, Enrique Santamaría, Joaquín Fernández-Irigoyen, María J Colomina, Isabel León Moreno, Antonio Martínez Yélamos, Sergio Martínez Yélamos, Gabriel Santpere, Elia Obis, Gerard Piñol-Ripoll, Mónica Povedano, Pol Andrés-Benito
Förderung
- Instituto de Salud Carlos III
- Fundació Catalana d'Esclerosi Lateral Amiotròfica (ELA) Miquel Valls
- Elles contra l'Esclerosi Lateral Amiotròfica (ELA)
- Swim for Esclerosi Lateral Amiotròfica (ELA)
- Mà amiga
- Association Européenne contre les Leucodystrophies
Zitieren
APA
Roca-Pereira, S., López-Sampere, Y., Mengod-Soler, P., Peña-Fonteboa, M., Marco, C., Caravaca-Puchades, A., Domínguez, R., Vázquez-Costa, J. F., Santamaría, E., Fernández-Irigoyen, J., Colomina, M. J., León Moreno, I., Martínez Yélamos, A., Martínez Yélamos, S., Santpere, G., Obis, E., Portero-Otín, M., Piñol-Ripoll, G., Povedano, M., & Andrés-Benito, P. (2026). Proteomic profile of CSF obtained at the time of diagnosis determines amyotrophic lateral sclerosis progression and survival: CXCL7 levels in disease prognosis and survival. Brain Pathology, 36(5). https://doi.org/10.1111/bpa.70089
Vancouver
Roca-Pereira S, López-Sampere Y, Mengod-Soler P, Peña-Fonteboa M, Marco C, Caravaca-Puchades A, et al. Proteomic profile of CSF obtained at the time of diagnosis determines amyotrophic lateral sclerosis progression and survival: CXCL7 levels in disease prognosis and survival. Brain Pathology. 2026;36(5). doi:10.1111/bpa.70089
BibTeX
@article{RocaPereira2026,
author = {Roca-Pereira, Sergio and López-Sampere, Yaiza and Mengod-Soler, Pol and Peña-Fonteboa, Mario and Marco, Carla and Caravaca-Puchades, Alejandro and Domínguez, Raúl and Vázquez-Costa, Juan Francisco and Santamaría, Enrique and Fernández-Irigoyen, Joaquín and Colomina, María J and León Moreno, Isabel and Martínez Yélamos, Antonio and Martínez Yélamos, Sergio and Santpere, Gabriel and Obis, Elia and Portero-Otín, Manuel and Piñol-Ripoll, Gerard and Povedano, Mónica and Andrés-Benito, Pol},
title = {Proteomic profile of CSF obtained at the time of diagnosis determines amyotrophic lateral sclerosis progression and survival: CXCL7 levels in disease prognosis and survival},
journal = {Brain Pathology},
year = {2026},
volume = {36},
number = {5},
doi = {10.1111/bpa.70089}
}
EUVIMED